Dr. Voss Discusses Neoadjuvant Trials of Immunotherapy in RCC
Martin H. Voss, MD
Martin H. Voss, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses neoadjuvant immunotherapy trials in renal cell carcinoma (RCC).
Given the data seen in the metastatic space, the field is moving toward immunotherapy-based approaches, says Voss. This is especially true for preoperative trials in non-metastatic disease.
The phase III PROSPER RCC trial (NCT03055013) is comparing nephrectomy with or without nivolumab (Opdivo), and is currently accruing in the United States.